CD274 and cutaneous melanoma: Genomic data from 6 other solid tumour types, which had been licensed by FDA to receive the anti‐PD‐1/PD‐L1 therapy (SKCM, skin cutaneous melanoma; KIRC, kidney renal clear cell carcinoma; LUSC, squamous cell carcinoma of the lung; LUAD, lung adenocarcinoma; HNSC, head and neck squamous cell carcinoma; BLCA, bladder carcinoma) were also retrieved.